Stereotaxis to Report Third Quarter Financial Results on November 10, 2022
Stereotaxis (NYSE: STXS) announced that it will release its third-quarter 2022 financial results on November 10, 2022, before U.S. markets open. A conference call will follow at 10 a.m. EST to discuss these results and corporate updates. The call can be accessed by dialing 800-715-9871 (US) or 1-646-307-1963 (International), using the passcode 5729833. This session aims to provide insights into Stereotaxis' performance in the surgical robotics sector and its ongoing developments in minimally invasive endovascular interventions.
- Scheduled announcement of Q3 2022 financial results could indicate confidence in performance.
- Conference call offers investors insight into corporate developments.
- None.
ST. LOUIS, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2022 third quarter on Thursday, November 10, 2022 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10 a.m. EST that day to discuss the Company’s results and corporate developments.
| What: | Stereotaxis third quarter 2022 financial results conference call |
| When: | Thursday, November 10, 2022, at 10:00 a.m. EST (7:00 a.m. PST) |
| Dial In Number: | To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) and give the participant pass code 5729833. |
| Webcast: | To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/. |
| Call Replay: | A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please click here. |
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.
| Investor Contacts: David L. Fischel Chairman and Chief Executive Officer | Media Contact: Bethanne Schluter Director, Marketing & Communications |
| Kimberly Peery Chief Financial Officer | |
| 314-678-6100 Investors@Stereotaxis.com |
FAQ
When will Stereotaxis release its Q3 2022 financial results?
What time is the Stereotaxis Q3 2022 results conference call?
How can investors access the Stereotaxis conference call?
Where can I find the replay of the Stereotaxis conference call?
